What matters most to patients when making treatment decisions for non-muscle invasive bladder cancer? In this cross over episode with BackTable Urology, Dr. Kelly Bree, Meredith Donahue, NP, Dr. Saum Ghodoussipour, and Dr. Vignesh Packiam discuss shared decision-making in NMIBC, including treatment selection, recurrence risk, quality of life considerations, and navigating conversations around escalation or de-escalation of care. Listen now on BackTable App: na2.hubs.ly/H065M_q0 #BladderCancer #NMIBC #UrologicOncology #MedEd #ONC65 #URO308

How are the ESOPEC & Matterhorn trials dethroning the long-standing CROSS backbone? @EricLanderMD & Dr. Michael Gibson break down the shift to upfront perioperative chemoimmunotherapy for gastric/GEJ cancers, managing FLOT toxicity, and the future of organ preservation. Listen to the full episode now: na2.hubs.ly/H062lhv0 #Oncology #GastricCancer #ClinicalTrials #ONC64

New NMIBC therapies mean higher patient volumes and more complexity. Is your clinic ready? On the latest collab episode with @_backtableUro, @BogdanaSchmidt, @AmyLuckenbaugh, and Meredith Donahue, DNP/APP, break down how to build a co-managed intravesical therapy clinic. Discover how they manage a 50-patient instillation day, tackle J-code hurdles, and coordinate with pharmacy teams to optimize patient outcomes. Listen now: na2.hubs.ly/H05_G7X0 This podcast is supported by an educational grant from Johnson & Johnson. #Urology #BladderCancer #URO306 #HealthcareOperations #ONC63

Community Playlists help you discover conversations curated by your peers. This Breast Cancer playlist created by Lindsay Peterson, brings together episodes covering biomarkers, treatment strategies, HER2-directed therapies, inflammatory breast cancer, and more. Explore community-created playlists and build your own in the BackTable App: na2.hubs.ly/H05XX1s0 #BreastCancer #Oncology #TumorBoard #MedEd

Can an "unresectable" pancreatic tumor actually be downstaged to surgery? On Ep. 62, @ZTBerman, Dr. Rebekah White, and @MV_Sherer discuss changing the paradigm for locally advanced pancreatic cancer. We dive into how tumor biology matters more than anatomy, the shift toward SBRT dose escalation in the triangle volume, the application of IRE NanoKnife, and the future of KRAS inhibitors. Listen here: na2.hubs.ly/H05WXx30 #PancreaticCancer #Oncology #TumorBoard #ONC62

Excited to support this @Onco_Nexus Academic & Community Oncology Panel during @ASCO this year. Looking forward to conversations bringing together perspectives across lung, breast, GI, and GU oncology as new data continues to shape cancer care across both academic and community settings. These are always some of the most valuable discussions coming out of ASCO each year. Register to attend in person or join the live stream: form.jotform.com/26112376258… 📍 Congress Plaza Hotel & Convention Center, May 29th | 6:00-9:15 PM #ASCO26 #Oncology #CancerResearch

In this @BTWomensHealth x Tumor Board crossover episode, Dr. Mona Guo (@xmGuo) and Dr. Marcia Ciccone are joined by USC radiation oncologist and brachytherapy director Dr. Andrew Lim to discuss how modern radiation advancements are shaping gynecologic cancer care. The conversation covers definitive and adjuvant radiation therapy, brachytherapy techniques, toxicity management, and how multidisciplinary collaboration helps tailor treatment for each patient. 🎧 Listen now: na2.hubs.ly/H05M3s80 #GynecologicOncology #RadiationOncology #Brachytherapy #ONC61

3 things Dr. Kate Baker is watching closely at #ASCO26 this year 👀 • RASolute 302 evaluating daraxonrasib in KRAS-mutated pancreatic cancer • HARMONi-6 and the continued development of ivonescimab in lung cancer • New ADC sequencing and combination data across solid tumors One of the most exciting parts of ASCO each year is seeing how quickly emerging science shapes real-world oncology conversations across both academic and community care settings. What presentations or abstracts are highest on your watch list this year? #ASCO #Oncology #CancerResearch #LungCancer #PancreaticCancer #MedEd

Managing side effects may be the key to maximizing PARP inhibitor benefit. Drs. Neeraj Agarwal & Arun Azad join Dr. Alan Tan to discuss PARP inhibitors in mCRPC, including side effect management, molecular testing, treatment sequencing, and the real-world barriers preventing patients from reaching later-line therapies. 🎧 Listen to Episode 60 in the BackTable app: na2.hubs.ly/H05GG-50 This podcast is supported by an educational grant from Pfizer. #ONC60 #UrologicOncology #ProstateCancer #PARPInhibitor #MedicalOncology

What if there was an effective treatment for hepatocellular carcinoma (HCC) that combines systemic immunotherapy with liver-directed therapies like Y90? In this final episode of the BackTable 2026 HCC Creator Weekend™, Dr. Lingling Du, Dr. A. Craig Lockhart, and Dr. Jon Mizrahi discuss what's next for the HCC landscape as it continues to evolve. What new targets and strategies are set to shape clinical practice in the near future? Listen to the full episode here: na2.hubs.ly/H05shR20 #HepatocellularCarcinoma #HCC #Immunotherapy #TargetedTherapy #ONC59

What comes after first-line immunotherapy in advanced hepatocellular carcinoma (HCC)? From tyrosine kinase inhibitor dosing to the limited role of next-generation sequencing, the following episode of the BackTable 2026 HCC Creator Weekend™ breaks down the complexities of second-line decision-making. Listen here: na2.hubs.ly/H05jh2J0 #HCC #MedicalOncology #SecondLine #HCCCreatorWeekend #ONC58

How did a single trial in 2020 overturn 10 years of standard care in #HCC? On TB57, Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the shift from TKIs to IO combinations. Check out the long-term survival "tails" that are changing the prognosis for advanced liver cancer. Listen here: na2.hubs.ly/H05bp2r0 #Oncology #LiverCancer #Immunotherapy #ONC57

Creator Weekend in Nashville is in the books! Four new episodes recorded, big conversations captured, and a weekend focused on advancing NMIBC care through multidisciplinary collaboration. 🎙️ Topics included: • Intravesical therapy clinic models • Shared decision-making • Risk stratification • Toxicity triage and supportive care Excited to share these episodes soon. #BTCreatorWeekend #UrologicOncology #BladderCancer

The BackTable App brings together expert conversations, courses, case discussions, and more - all in one place! Already listening? Download the BackTable App: na2.hubs.ly/H0552Rc0 #MedEd #ClinicalLearning

Explore how tumor biomarkers enable personalized breast cancer treatment while helping reduce financial toxicity in precision medicine. In this new episode of BackTable Tumor Board, Dr. Jessica Treviño Jones and Dr. Lindsay Peterson cover how genomic testing, technological advances, current research, and patient education inform treatment selection for both early-stage and metastatic breast cancer. Tune in for the full episode here: na2.hubs.ly/H050Wrn0 Or visit na2.hubs.ly/H050Wk30 #BreastCancer #MetastaticBreastCancer #MedicalOncology #PrecisionMedicine #Biomarkers #ONC56

How will the latest colorectal cancer data change practice? At the 2026 ASCO GI Symposium in San Francisco, trials like BREAKWATER, COMMIT, ATOMIC, and CHALLENGE are redefining treatment strategies. On the latest BackTable Tumor Board episode, Dr. Shruti Patel and Dr. Jun Gong break down what these trials reveal about where colorectal cancer management is headed next. Listen here: na2.hubs.ly/H04TSXl0 or visit na2.hubs.ly/H04TRSn0 #ColorectalCancer #2026GIASCO #MedicalOncology #Phase3ClinicalTrials #ONC55

You know BackTable. Now make it yours. Inside the app: - A For You feed built around your specialty - Search across clinical topics - Real clinical case discussions - And more Download the BackTable App: na2.hubs.ly/H04Q49m0